167 related articles for article (PubMed ID: 33864703)
21. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.
Frenkel S; Hendler K; Siegal T; Shalom E; Pe'er J
Br J Ophthalmol; 2008 Mar; 92(3):383-8. PubMed ID: 18303160
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of HD-MTX based systemic chemotherapy regimens: retrospective study of induction therapy for primary central nervous system lymphoma in Chinese.
Han X; Ji Y; Ouyang M; Zhu T; Zhou D
Sci Rep; 2017 Dec; 7(1):17053. PubMed ID: 29213063
[TBL] [Abstract][Full Text] [Related]
23. Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population.
Mahajan S; Nijhawan R; Rajwanshi A; Karkhur S; Mulkutar S; Dogra M; Lal V; Gupta V; Gupta A
Ocul Immunol Inflamm; 2017 Oct; 25(5):633-638. PubMed ID: 27003620
[TBL] [Abstract][Full Text] [Related]
24. Neoplastic lymphomatous submaculopathy.
Testi I; Agarwal A; Gupta V;
Indian J Ophthalmol; 2019 Dec; 67(12):2051-2052. PubMed ID: 31755451
[No Abstract] [Full Text] [Related]
25. Changes in choroidal vascular structure from vitreoretinal lymphoma and the intraocular cytokine level associated with clinical resolution after intravitreal methotrexate treatment.
Kim RY; Park JH; Kim M; Park YG; Cho SG; Park YH
PLoS One; 2021; 16(11):e0260469. PubMed ID: 34813633
[TBL] [Abstract][Full Text] [Related]
26. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
27. Stereotactic radiosurgery in combination with up-front high-dose methotrexate as a first-line treatment for newly diagnosed primary central nervous system lymphoma.
Hirono S; Iwadate Y; Higuchi Y; Serizawa T; Nagano O; Matsutani T; Saeki N
J Neurooncol; 2015 Jun; 123(2):237-44. PubMed ID: 25911295
[TBL] [Abstract][Full Text] [Related]
28. Clinical factors for central nervous system progression and survival in primary vitreoretinal lymphoma.
Motomura Y; Yoshifuji K; Tachibana T; Takase H; Arai A; Tanaka K; Okada K; Nogami A; Umezawa Y; Sakashita C; Yamamoto M; Mori T; Nagao T
Br J Haematol; 2024 Apr; 204(4):1279-1287. PubMed ID: 38131400
[TBL] [Abstract][Full Text] [Related]
29. Isolated intraocular relapses of primary cerebral lymphomas: An LOC network study.
Younan N; Soussain C; Choquet S; Cassoux N; Touitou V; Schmitt A; Chinot O; Oberic L; Damaj G; Houot R; Ghesquières H; Laribi K; Ahle G; Taillandier L; Paillassa J; Gyan E; Jardin F; Delwail V; Marolleau JP; Tempescul A; Agapé P; Bourniquel M; Vacheret F; Jdid I; Le Garff-Tavernier M; Malaise D; Alentorn A; Xuan KH; Houillier C
Hematol Oncol; 2022 Dec; 40(5):976-986. PubMed ID: 35789106
[TBL] [Abstract][Full Text] [Related]
30. Is intrathecal methotrexate necessary in the treatment of primary CNS lymphoma?
Khan RB; Shi W; Thaler HT; DeAngelis LM; Abrey LE
J Neurooncol; 2002 Jun; 58(2):175-8. PubMed ID: 12164690
[TBL] [Abstract][Full Text] [Related]
31. Secondary central nervous system (CNS) involvement in patients with diffuse large B-cell lymphoma: a therapeutic dilemma.
Kim SJ; Oh SY; Kim JS; Kim H; Lee GW; Won JH; Shin HJ; Yang DH; Choi CW; Park J; Kim WS; Suh C
Ann Hematol; 2011 May; 90(5):539-46. PubMed ID: 20960190
[TBL] [Abstract][Full Text] [Related]
32. Clinical Experience in a Large Cohort of Patients with Vitreoretinal Lymphoma in a Single Center.
Giuffrè C; Cicinelli MV; Marchese A; Modorati GM; Brambati M; Ferreri AJM; Calimeri T; Ponzoni M; Bandello F; Miserocchi E
Ocul Immunol Inflamm; 2021 Apr; 29(3):472-478. PubMed ID: 32845738
[No Abstract] [Full Text] [Related]
33. Efficacy and safety of first-line combination therapy versus monotherapy for vitreoretinal lymphoma: a systematic review and meta-analysis.
Gao J; Peng X; Wang L
BMC Ophthalmol; 2023 Nov; 23(1):477. PubMed ID: 37993841
[TBL] [Abstract][Full Text] [Related]
34. How we diagnose and treat vitreoretinal lymphoma.
Fend F; Ferreri AJ; Coupland SE
Br J Haematol; 2016 Jun; 173(5):680-92. PubMed ID: 27133587
[TBL] [Abstract][Full Text] [Related]
35. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
[TBL] [Abstract][Full Text] [Related]
36. CLINICAL FEATURES, DIAGNOSTIC SIGNIFICANCE, AND PROGNOSIS OF VITREORETINAL LYMPHOMA IN YOUNG PATIENTS.
Liu S; Gu J; Zhang T; Ping B; Zhou M; Huang X; Jiang R; Xu G; Chang Q
Retina; 2021 Dec; 41(12):2596-2604. PubMed ID: 34173362
[TBL] [Abstract][Full Text] [Related]
37. Long-term AIDS-related PCNSL outcomes with HD-MTX and combined antiretroviral therapy.
Moulignier A; Lamirel C; Picard H; Lebrette MG; Amiel C; Hamidi M; Polivka M; Mikol J; Cochereau I; Pialoux G
Neurology; 2017 Aug; 89(8):796-804. PubMed ID: 28747447
[TBL] [Abstract][Full Text] [Related]
38. Combined treatment with high-dose methotrexate, vincristine and procarbazine, without intrathecal chemotherapy, followed by consolidation radiotherapy for primary central nervous system lymphoma in immunocompetent patients.
Ferreri AJ; Reni M; Dell'Oro S; Ciceri F; Bernardi M; Camba L; Ponzoni M; Terreni MR; Tomirotti M; Spina M; Villa E
Oncology; 2001; 60(2):134-40. PubMed ID: 11244328
[TBL] [Abstract][Full Text] [Related]
39. High-dose methotrexate for intraocular lymphoma.
Batchelor TT; Kolak G; Ciordia R; Foster CS; Henson JW
Clin Cancer Res; 2003 Feb; 9(2):711-5. PubMed ID: 12576439
[TBL] [Abstract][Full Text] [Related]
40. Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients.
Zhou X; Zhou X; Shi H; Lai J; Wang Q; Li Y; Chen K; Li Q; Zhou Q; Cao X; Chen B; Xiao J
BMC Ophthalmol; 2020 May; 20(1):189. PubMed ID: 32397978
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
